OA11636A - Therapeutic formulation for administering tolterodine with controlled release. - Google Patents
Therapeutic formulation for administering tolterodine with controlled release. Download PDFInfo
- Publication number
- OA11636A OA11636A OA1200000309A OA1200000309A OA11636A OA 11636 A OA11636 A OA 11636A OA 1200000309 A OA1200000309 A OA 1200000309A OA 1200000309 A OA1200000309 A OA 1200000309A OA 11636 A OA11636 A OA 11636A
- Authority
- OA
- OAPI
- Prior art keywords
- tolterodine
- sérum
- formulation
- métabolite
- daims
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9802864A SE9802864D0 (sv) | 1998-08-27 | 1998-08-27 | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
SE9803871A SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Therapeutic method and formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
OA11636A true OA11636A (en) | 2004-09-03 |
Family
ID=26663376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200000309A OA11636A (en) | 1998-08-27 | 1999-08-26 | Therapeutic formulation for administering tolterodine with controlled release. |
Country Status (31)
Country | Link |
---|---|
US (1) | US6770295B1 (fr) |
EP (2) | EP1039882B1 (fr) |
CN (1) | CN1239152C (fr) |
AP (1) | AP1529A (fr) |
AR (1) | AR029311A1 (fr) |
AT (1) | ATE487471T1 (fr) |
AU (1) | AU745190B2 (fr) |
BG (1) | BG65168B1 (fr) |
CA (1) | CA2311755C (fr) |
CY (1) | CY1111088T1 (fr) |
CZ (1) | CZ302630B6 (fr) |
DE (1) | DE69942928D1 (fr) |
DK (1) | DK1039882T3 (fr) |
EA (1) | EA002720B1 (fr) |
GE (1) | GEP20043354B (fr) |
HK (1) | HK1034664A1 (fr) |
HU (1) | HUP0100437A3 (fr) |
ID (1) | ID25824A (fr) |
IL (1) | IL136294A (fr) |
IS (1) | IS2976B (fr) |
ME (1) | ME00850B (fr) |
MY (1) | MY127946A (fr) |
NO (1) | NO329830B1 (fr) |
NZ (1) | NZ504618A (fr) |
OA (1) | OA11636A (fr) |
PT (1) | PT1039882E (fr) |
SI (1) | SI1039882T1 (fr) |
SK (1) | SK287111B6 (fr) |
TR (1) | TR200001998T1 (fr) |
UA (1) | UA72882C2 (fr) |
WO (1) | WO2000012069A1 (fr) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0957073A1 (fr) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Dérivés de 3,3-diphénylpropylamines |
DE19922662C1 (de) | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches System (TTS) Tolterodin enthaltend |
DE19932651A1 (de) * | 1999-07-13 | 2001-01-18 | Hexal Ag | Transdermales therapeutisches System zur Anwendung von Tolterodin |
EE05191B1 (et) * | 1999-11-11 | 2009-08-17 | Pharmacia Ab | Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine |
DE10149674A1 (de) | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
US20030185882A1 (en) | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
MXPA04003866A (es) * | 2001-11-09 | 2004-07-08 | Pharmacia Ab | Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva. |
US6773421B2 (en) | 2001-12-14 | 2004-08-10 | Kimberly-Clark Worlwide, Inc. | Combination for managing the involuntary loss of bladder control |
EP1424079A1 (fr) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine |
WO2004054560A1 (fr) * | 2002-12-13 | 2004-07-01 | Warner-Lambert Company Llc | Ligand alpha-2-delta pour traiter des symptomes des voies urinaires inferieures |
KR20050096147A (ko) * | 2003-01-22 | 2005-10-05 | 피저 헬스 에이비 | 비뇨기 장애 치료용 톨테로딘 및 다른 항무스카린제의감소량 투여 |
DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
WO2004105735A1 (fr) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Compositions pharmaceutiques de tolterodine a liberation controlee et leurs procedes de preparation |
ATE493981T1 (de) | 2003-11-04 | 2011-01-15 | Supernus Pharmaceuticals Inc | Einmal tägliche dosierformen von trospium |
US8709476B2 (en) | 2003-11-04 | 2014-04-29 | Supernus Pharmaceuticals, Inc. | Compositions of quaternary ammonium compounds containing bioavailability enhancers |
WO2005105036A1 (fr) * | 2004-04-28 | 2005-11-10 | Natco Pharma Limited | Matrice muco-adhesive a liberation controlee contenant de la tolterodine, et procede d'elaboration |
EP1629834A1 (fr) † | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Composition pharmaceutique de tolterodine avec liberation soutenue |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
CA2604052C (fr) * | 2005-04-06 | 2014-07-08 | Adamas Pharmaceuticals, Inc. | Methode et compositions de traitement des affections du snc |
CN1330297C (zh) * | 2005-07-04 | 2007-08-08 | 宛六一 | 酒石酸托特罗定软胶囊及其制备方法 |
KR20070012205A (ko) * | 2005-07-22 | 2007-01-25 | 주식회사종근당 | 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛 |
ES2593047T3 (es) | 2006-02-03 | 2016-12-05 | Opko Renal, Llc | Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3 |
WO2007122015A1 (fr) * | 2006-04-21 | 2007-11-01 | Synthon B.V. | Perles de tolterodine |
ES2670029T3 (es) | 2006-06-21 | 2018-05-29 | Opko Ireland Global Holdings, Ltd. | Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D |
US20100144684A1 (en) | 2007-04-25 | 2010-06-10 | Proventiv Therapeutics, Inc. | Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease |
EP2762132A1 (fr) | 2007-04-25 | 2014-08-06 | Cytochroma Inc. | Compositions orales à libération contrôlée comprenant des composés de vitamine D et un véhicule cireux |
DK2148684T3 (da) | 2007-04-25 | 2013-04-22 | Cytochroma Inc | Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens |
CL2008001970A1 (es) * | 2007-07-03 | 2009-03-27 | Synthon Bv | Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva. |
US8486452B2 (en) * | 2007-07-20 | 2013-07-16 | Mylan Pharmaceuticals Inc. | Stabilized tolterodine tartrate formulations |
WO2009019599A2 (fr) | 2007-08-08 | 2009-02-12 | Themis Laboratories Private Limited | Compositions à libération prolongée comprenant de la toltérodine |
US20090192228A1 (en) * | 2008-01-28 | 2009-07-30 | Actavis Group Ptc Ehf | Controlled-Release Tolterodine Compositions and Methods |
US20090214665A1 (en) * | 2008-02-26 | 2009-08-27 | Lai Felix S | Controlled Release Muscarinic Receptor Antagonist Formulation |
CN106853250A (zh) | 2008-04-02 | 2017-06-16 | 赛特克罗公司 | 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒 |
TWI541246B (zh) | 2008-12-08 | 2016-07-11 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
KR101004205B1 (ko) * | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
WO2011095388A1 (fr) | 2010-02-04 | 2011-08-11 | Synthon Bv | Microgranule de toltérodine |
KR101746204B1 (ko) * | 2010-02-18 | 2017-06-13 | 에스케이케미칼주식회사 | 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물 |
PT2552484T (pt) | 2010-03-29 | 2020-04-03 | Opko Ireland Global Holdings Ltd | Métodos e composições para redução dos níveis de parafróides |
AU2011245499B2 (en) | 2010-04-30 | 2014-09-25 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
US20130195957A1 (en) * | 2010-08-03 | 2013-08-01 | Hisamitsu Pharmaceutical Co., Inc. | Patch and method for enhancing adhesion force of the same |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
SG10201911274TA (en) | 2014-08-07 | 2020-02-27 | Opko Ireland Global Holdings Ltd | Adjunctive therapy with 25-hydroxyvitamin d |
TWI747893B (zh) | 2016-03-28 | 2021-12-01 | 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 | 維生素d治療之方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
SE8800207D0 (sv) | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | Nya aminer, deras anvendning och framstellning |
US5382600A (en) * | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
JP3786684B2 (ja) | 1992-05-13 | 2006-06-14 | アルザ・コーポレーション | オキシブチニンの経皮投与 |
SE9203318D0 (sv) | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
WO1996012477A1 (fr) | 1994-10-21 | 1996-05-02 | Leiras Oy | Systeme d'administration orale a liberation lente contenant de l'oxybutynine |
US5677346A (en) * | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
JP2000515525A (ja) * | 1996-07-19 | 2000-11-21 | アベーグ,グンナー | 尿と胃腸の疾患の治療におけるs(―)―トルテロジン |
EP0927034A1 (fr) * | 1996-09-19 | 1999-07-07 | American Home Products Corporation | Procede de traitement de l'incontinence urinaire |
-
1999
- 1999-08-26 MY MYPI99003665A patent/MY127946A/en unknown
- 1999-08-26 AP APAP/P/2000/001823A patent/AP1529A/en active
- 1999-08-26 NZ NZ504618A patent/NZ504618A/xx not_active IP Right Cessation
- 1999-08-26 ID IDP20001006A patent/ID25824A/id unknown
- 1999-08-26 UA UA2000052950A patent/UA72882C2/uk unknown
- 1999-08-26 AR ARP990104280A patent/AR029311A1/es not_active Application Discontinuation
- 1999-08-26 WO PCT/SE1999/001463 patent/WO2000012069A1/fr active Application Filing
- 1999-08-26 DE DE69942928T patent/DE69942928D1/de not_active Expired - Lifetime
- 1999-08-26 AU AU58918/99A patent/AU745190B2/en not_active Expired
- 1999-08-26 DK DK99946521.4T patent/DK1039882T3/da active
- 1999-08-26 OA OA1200000309A patent/OA11636A/en unknown
- 1999-08-26 PT PT99946521T patent/PT1039882E/pt unknown
- 1999-08-26 EA EA200000468A patent/EA002720B1/ru not_active IP Right Cessation
- 1999-08-26 ME MEP-2001-331A patent/ME00850B/fr unknown
- 1999-08-26 AT AT99946521T patent/ATE487471T1/de active
- 1999-08-26 SI SI9931050T patent/SI1039882T1/sl unknown
- 1999-08-26 GE GE3951A patent/GEP20043354B/en unknown
- 1999-08-26 SK SK749-2000A patent/SK287111B6/sk not_active IP Right Cessation
- 1999-08-26 EP EP99946521A patent/EP1039882B1/fr not_active Revoked
- 1999-08-26 IL IL13629499A patent/IL136294A/en unknown
- 1999-08-26 TR TR2000/01998T patent/TR200001998T1/xx unknown
- 1999-08-26 CZ CZ20001924A patent/CZ302630B6/cs not_active IP Right Cessation
- 1999-08-26 CA CA2311755A patent/CA2311755C/fr not_active Expired - Lifetime
- 1999-08-26 EP EP09173927A patent/EP2153825A1/fr not_active Withdrawn
- 1999-08-26 US US09/582,498 patent/US6770295B1/en not_active Expired - Lifetime
- 1999-08-26 HU HU0100437A patent/HUP0100437A3/hu unknown
- 1999-08-26 CN CNB99801916XA patent/CN1239152C/zh not_active Expired - Lifetime
-
2000
- 2000-05-26 BG BG104476A patent/BG65168B1/bg unknown
- 2000-06-09 NO NO20002977A patent/NO329830B1/no not_active IP Right Cessation
- 2000-06-15 IS IS5537A patent/IS2976B/is unknown
-
2001
- 2001-07-12 HK HK01104868A patent/HK1034664A1/xx not_active IP Right Cessation
-
2010
- 2010-11-17 CY CY20101101027T patent/CY1111088T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA11636A (en) | Therapeutic formulation for administering tolterodine with controlled release. | |
ES2353765T3 (es) | Formulación terapeútica para administrar tolterodina con liberación controlada. | |
US6630162B1 (en) | Pharmaceutical formulation and its use | |
TWI222879B (en) | Release-controlled pharmaceutical compositions for treating dysfunction of urinary bladder | |
US9375410B2 (en) | Modified release dosage forms of skeletal muscle relaxants | |
MXPA00005215A (en) | Therapeutic formulation for administering tolterodine with controlled release |